Compare Repligen Corporation Common Stock (RGEN) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Invesco S&P 500 Momentum ETF — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Invesco S&P 500 Momentum ETF trades at $144 (market cap $23.04B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 2.1× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Invesco S&P 500 Momentum ETF for 55 Days on average.
| RGEN | SPMO | |
|---|---|---|
Market Cap | $11.14B | $23.04B |
Volume | 1,259,263 | 2,008,654 |
Sector | Health | Broad Market / Factor |
52-Week High | $194.57 | $161.66 |
52-Week Low | $102.87 | $107.84 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SPMO, the Invesco S&P 500 Momentum ETF, trades at $148.03, down 0.89% on the day amid a bearish technical signal. The ETF recently completed its semi-annual reconstitution, adding 54 stocks including Apple and Merck while removing Nvidia. Its momentum strategy has historically outperformed the S&P 500 but faces near-term volatility from concentrated sector exposure.
Outlook remains mixed with strong long-term momentum performance offset by current technical weakness. Investment opportunity lies in capturing S&P 500's fastest-rising stocks, though risks include high volatility and sector concentration. The ETF's structural edge suggests potential for continued outperformance despite recent underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
